Slingshot members are tracking this event:

AstraZeneca (AZN) releases positive results from a Phase 3 trial OLYMPIAD, which evaluates LYNPARZA (olaparib) in treating HER2-negative, BRCA1- or BRCA2-positive breast cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
AZN Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 17, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Olympiad, Phase 3, Lynparza, Olaparib, Her2-negative, Brca Breast Cancer